What is the optimal blood pressure and drug therapy for patients with coronary artery disease?

JAMA

Volumn 292, Issue 18, 2004, Pages 2271-2273

  Pepine, Carl J ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ASTRAZENECA   (United Kingdom)

^d SANOFI   (France)

^e BAYER PHARMA AG   (Germany)

^f CV THERAPEUTICS INC   (United States)

^g King Pharmaceuticals   (United States)

^h Monarch Pharmaceuticals   (United States)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIARRHYTHMIC AGENT; ATENOLOL; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; PHOSPHODIESTERASE; ROFECOXIB; STATIN; TRANDOLAPRIL PLUS VERAPAMIL; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; EDITORIAL; HEART INFARCTION; HUMAN; INTRAVASCULAR ULTRASOUND; PRIORITY JOURNAL; STROKE; SUDDEN DEATH; THROMBOSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; NOTE; RISK;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; HUMANS; RISK;

EID: 7744243662     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.18.2271     Document Type: Editorial

References (12)

1. Wessel TR, Arant CB, Olson MB, et al. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA. 2004;292:1179-1187.
2. A Public Health Action Plan to Prevent Heart Disease and Stroke. Atlanta, Ga: Centers for Disease Control and Prevention; 2003. Available at: http://www.gov/cvh/Action_Plan/pdf/action_plan_full.pdf. Accessibility verified October 18, 2004.
3. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al; for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290:2805-2816.
4. Nissen SE, Tuzcu EM, Libby P, et al; for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2226.
5. Mancia G, Cooper-DeHoff RM, Hewkin AC, Kupfer SR, Repine CJ. Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the INternational VErapamil SR-trandolapril STudy. Am J Hypertens. 2004;17:116A.
6. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292-2300.
7. Nissen SE, Tuzcu EM, Schoenhagen P, et al; for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA. 2004;291:1071-1080.
8. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
9. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
10. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl. J Am Coll Cardiol. 2004;43:2142-2146.
11. Elliott P. High blood pressure in the community. In: Bulpitt CJ, ed. Handbook of Hypertension. Amsterdam, the Netherlands: Elsevier Science; 2000:1-18. Epidemiology of Hypertension, vol 20.
12. Elliott P. High blood pressure in the community. In: Bulpitt CJ, ed. Handbook of Hypertension. Amsterdam, the Netherlands: Elsevier Science; 2000:1-18. Epidemiology of Hypertension, vol 20.